Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
The DOI matches its Crossref record.
Abstract
BACKGROUND: Escitalopram is the single isomer responsible for the serotonin reuptake inhibition produced by the racemic antidepressant citalopram. The present randomized, double-blind, placebo-controlled, fixed-dose multicenter trial was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of major depressive disorder. METHOD: Outpatients with an ongoing DSM-IV major depressive episode (N = 491) were randomly assigned to placebo, escitalopram, 10 mg/day, escitalopram, 20 mg/day, or citalopram, 40 mg/day, and entered an 8-week double-blind treatment period following a 1-week single-blind placebo lead-in. Clinical response was evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS), the 24-item Hamilton Rating Scale for Depression (HAM-D), the Clinical Global Impressions (CGI) scales, the Hamilton Rating Scale for Anxiety (HAM-A), and patient-rated quality-of-life scales. RESULTS: Escitalopram, at both doses, produced significant improvement at study endpoint relative to placebo on all measures of depression; significant separation of escitalopram from placebo was observed within I week of double-blind treatment. Citalopram treatment also significantly improved depressive symptomatology compared with placebo; however, escitalopram, 10 mg/day, was at least as effective as citalopram, 40 mg/day, at endpoint. Anxiety symptoms and quality of life were also significantly improved by escitalopram compared with placebo. The incidence of discontinuations due to adverse events for the escitalopram 10 mg/day group was not different from the placebo group (4.2% vs. 2.5%; p = .50), and not different for the escitalopram 20 mg/day group and the citalopram 40 mg/day group (10.4% vs. 8.8%; p = .83). CONCLUSION: Escitalopram, a single isomer SSRI, is well-tolerated and has demonstrated antidepressant efficacy at a dose of 10 mg/day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Baum, L., Lam, C. W. K., Cheung, S. K.-K., Kwok, T., Lui, V., Tsoh, J., Lam, L., Leung, V., Hui, E., Ng, C., et al. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318160862c · Cited by 592
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355
Papakostas, G. I., Nutt, D. J., Hallett, L. A., Tucker, V. L., Krishen, A., & Fava, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.015 · Cited by 334
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Stereochemistry in Drug Action
McConathy, J., & Owens, M. J. (2003) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v05n0202 · Cited by 294
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269
Sánchez, C., Bergqvist, P. B. F., Brennum, L. T., Gupta, S., Hogg, S., Larsen, A., & Wiborg, O. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1364-z · Cited by 265
The Clinical Pharmacokinetics of Escitalopram
Rao, N. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746040-00002 · Cited by 256
Hansen, R. A., Gartlehner, G., Lohr, K. N., Gaynes, B. N., & Carey, T. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-6-200509200-00006 · Cited by 255
Rief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J. (2009) · Drug Safety · doi:10.2165/11316580-000000000-00000 · Cited by 202
“A total of 143 studies([14-155]) 2 including 12 742 patients (11 719 in SSRI placebo groups, 1023 in TCA placebo groups) were analysed (see figure 1).”
BackgroundEscitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Brunoni, A. R., Lopes, M., Kaptchuk, T. J., & Fregni, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004824 · Cited by 173
“Many escitalopram studies did not report SD final scores – in these cases, we calculated SD from standard error (SE) at end-of-treatment or from SD or SE difference changes when possible [11,12].”
MethodLader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
“Recently completed studies have demonstrated the efficacy and tolerability of escitalopram in the shortand long-term treatment of major depressive disorder (MDD) and in the short-term treatment of SAD [Burke et al., 2002; Kasper et al., 2002; Lepola et al., 2003; Wade et al., 2002a,b].”
BackgroundReichenpfader, U., Gartlehner, G., Morgan, L. C., Greenblatt, A., Nussbaumer, B., Hansen, R. A., Van Noord, M., Lux, L., & Gaynes, B. N. (2014) · Drug Safety · doi:10.1007/s40264-013-0129-4 · Cited by 160
“eligibility criteria we could finally include 37 RCTs [26-62] meeting the statistical”
Gartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00004 · Cited by 150
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Self-citationMontgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115
Baldwin, D. S., Huusom, A. K. T., & Mæhlum, E. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.012799 · Cited by 114
An open-label, flexible-dose study of memantine in major depressive disorder
Ferguson, J. M., & Shingleton, R. N. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3180314ae7 · Cited by 113
“7 on the HAM-D24 at study end point (8 weeks).(33) In another trial involving the serotonin-norepinephrine reuptake inhibitor duloxetine (80 or 100 mg/d) and the selective serotonin reuptake inhibitor paroxetine (20 mg/d), mean changes from baseline ranged from j12.”
BackgroundMethodBaldwin, D. S., Cooper, J. A., Huusom, A. K. T., & Hindmarch, I. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194377.88330.1d · Cited by 100
Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194375.42589.c3 · Cited by 100
Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Kornstein, S. G., Bose, A., Li, D., Saikali, K. G., & Gandhi, C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1115 · Cited by 60
Self-citationPET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram
Lundberg, J., Christophersen, J. S., Petersen, K. B., Loft, H., Halldin, C., & Farde, L. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007486 · Cited by 55
Social phobia is associated with suicide attempt history in bipolar inpatients
Perroud, N., Baud, P., Preisig, M., Etain, B., Bellivier, F., Favre, S., Reber, N., Ferrero, F., Leboyer, M., & Malafosse, A. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00471.x · Cited by 55
Amidfar, M., Réus, G. Z., Quevedo, J., & Kim, Y.-K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.023 · Cited by 43
Dose-response relationship of recent antidepressants in the short-term treatment of depression
Berney, P. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/pberney · Cited by 39
Braun, C., Adams, A., Rink, L., Bschor, T., Kuhr, K., & Baethge, C. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13235 · Cited by 36
“488 Unclear (3); high (1) Citalopram 40 vs.”
The effect of escitalopram on sleep problems in depressed patients
Lader, M., Andersen, H. F., & Bækdal, T. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.694 · Cited by 34
Efficacy and safety of escitalopram in treatment of severe depression in Chinese population
Si, T., Wang, G., Yang, F., Fang, Y., Fang, M., Li, J., Dong, J., Shen, X., Zhuo, J., Rui, Q., et al. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-9992-5 · Cited by 20
“The results of this study corroborated the findings of earlier global studies conducted across different settings and different populations (Burke et al. 2002; Lepola et al. 2003; Mao et al. 2008; Moore et al. 2005; Wade et al. 2002).”
ResultSafer, D. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000564 · Cited by 19
Jiang, K., Li, L., Xueyi, W., Fang, M., Shi, J., Cao, Q., He, J., Wang, J., Tan, W., & Hu, C. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s120190 · Cited by 18
“22,23 The efficacy of escitalopram in the treatment of MDD with anxiety symptoms has been established in short-term (8–12 weeks) studies, 16,24,25 while the data on the long-term treatment with escitalopram in these patients are insufficient.”
Metadata
- Authors
- Burke, W. J., Gergel, I., & Bose, A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-04-15
- Volume
- 63
- Issue
- 4
- Pages
- 331-336
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1982377331
- Cited by
- 350
- References
- 0
- FWCI
- 16.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.